Skip to main navigation
Fulcrum Therapeutics logo
Menu Button

Main Menu

  • About
  • Our Approach
  • Pipeline
    • Publications
  • Therapeutic Focus
    • FSHD
    • SCD
    • Beta-thalassemia
  • Careers
    • Current Openings
    • Faces of Fulcrum
  • Investor Relations
    • News Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
  • Contact

News Releases

News Releases

Sep 22, 2023
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
Sep 15, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 07, 2023
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Aug 22, 2023
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
Aug 11, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 03, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
Aug 03, 2023
Fulcrum Therapeutics Appoints Chief Financial Officer
Jul 27, 2023
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
Jul 10, 2023
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
Jul 07, 2023
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 29

Investor Tools

Print
Email Page
Email Alerts
IR Contact
Code of Conduct & Business Ethics
Privacy Policy | EU Privacy Policy | Terms of use
Fulcrum TX
Social Media Guidelines

Main Menu

  • About
  • Our Approach
  • Pipeline
    • Publications
  • Therapeutic Focus
    • FSHD
    • SCD
    • Beta-thalassemia
  • Careers
    • Current Openings
    • Faces of Fulcrum
  • Investor Relations
    • News Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
  • Contact